Lantheus Holdings Inc
NASDAQ:LNTH
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
51.07
123.62
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Lantheus Holdings Inc
You don't have any saved screeners yet
Good morning, ladies and gentlemen. And welcome to Lantheus Fourth Quarter 2022 Financial Results Conference Call. This is your operator for today's call. Please note that all lines have been placed on mute to prevent any background noise. This call is being recorded for replay purposes. A replay of the webcast will be available in the Investor Section of the company's website, approximately two hours after the completion of the call and will be archived for 30 days.
I'll now turn the call over to your host for today's call, Mark Kinarney, Senior Director of Investor Relations. Mark?
Thank you and good morning. Welcome to Lantheus' first quarter 2022 financial results conference call.
With me on today's call are Mary Anne Heino, our President and CEO; Bob Marshall, our Chief Financial Officer; and Paul Blanchfield, our Chief Commercial Officer. Mary Anne will begin the call with introductory remarks and then turn the call over to Paul to provide a commercial update. Bob will cover our financial results and updated guidance. Mary Anne will provide closing remarks, and then we will open the call for Q&A.
This morning, we issued a press release, which was furnished to the Securities and Exchange Commission under Form 8-K, reporting our first quarter 2022 results. You can find the release in the Investors section of our website at lantheus.com. For those of you not on the webcast, you can find the slide presentation on the Investors section of our website under the Presentations tab.
Before we get started, I would like to remind you that our comments today during this call will include forward-looking statements. Actual results may differ materially from those indicated by forward-looking statements due to a variety of risks and uncertainties. In particular, the impact of hospital staffing levels and COVID-19 on our business results and outlook continues to be a best estimate based on currently available information.
Please note that we assume no obligation to update these forward-looking statements, except as required by applicable law, even if actual results or future expectations change materially. Please refer to our SEC filings for a detailed discussion of these risks and uncertainties.
Also, discussions during the call will include certain non-GAAP financial measures. Reconciliation of these measures to the most directly comparable GAAP financial measures is also included on the Investors section of our website.
With that, it's my pleasure to now turn the call over to Mary Anne.
Thank you, Mark. And good morning to everyone joining us. I am pleased to say we have very positive news to share today. Lantheus reported a record quarter led by rapidly increasing PYLARIFY sales and solid DEFINITY performance. We continue to execute on our strategy to accelerate growth, positioning Lantheus as a category leader in the markets in which we compete, and pursue our passion to find, fight and follow disease to deliver better patient outcomes.
As the year continues, we are focused on further establishing PYLARIFY as a PSMA PET imaging agent of choice in the USA prostate cancer community, maintaining market leadership with our Microbubble franchise, executing strategic transactions in line with our portfolio objectives, and delivering on our financial objectives which we believe best enhance shareholder value.
I'll now take a few minutes to update you on our progress. It has been an exciting and transformational time for prostate cancer care, with advances in technology and new FDA approvals in both diagnostics and therapeutics. Paul will provide further details on the PYLARIFY launch to date in a few minutes, but I am thrilled that less than one year after we commenced our launch, more than 30,000 men have been imaged with PYLARIFY, including more than 20,000 in the first quarter of 2022 alone. This is a testament to the innovation of our PSMA-targeted PET imaging agent and our efforts to transform patient management for the US prostate cancer community.
Now, let me take a few minutes to highlight our recent strategic collaborations with PYLARIFY. First, in March, we announced a collaboration with Novartis to include PYLARIFY in their planned development programs for Pluvicto, their recently approved PSMA-targeted therapeutic for metastatic castration resistant prostate cancer. This collaboration builds on PYLARIFY's inclusion in their expanded access trial for Pluvicto, and directly aligns with our strategy to advance precision medicine in the treatment of cancer by enabling partners to use PYLARIFY in ongoing prostate cancer therapeutic trials.
As part of the agreement with Novartis, we will supply PYLARIFY for the selection of patients within their trials and Novartis, in turn, will provide Lantheus with all PYLARIFY related clinical imaging data from these trials.
During the quarter, we also entered into two strategic collaborations to advance our artificial intelligence or AI-enabled imaging biomarkers for prostate cancer. In January, we announced a collaboration with the Prostate Cancer Clinical Trials Consortium or PCCTC, a premier multicenter clinical research organization that specializes in cutting-edge prostate cancer research. The intent of this strategic collaboration is to integrate Lantheus' AI platform is the early phase PCCTC studies to advance the discovery, development and validation of novel AI-enabled biomarkers.
And earlier this month, we expanded our collaboration with GE Healthcare to include AI-enabled aPROMISE on their latest platform. As a leading supplier of medical technology equipment, GE Healthcare is an ideal partner to provide global access to this unique AI platform for prostate cancer.
Turning to DEFINITY, our market leading ultrasound enhancing agent, and our Microbubble franchise. Sales continued to grow despite widely reported hospital staffing challenges and record high COVID-19 levels early in the quarter. We are pleased to see that DEFINITY sales have steadily increased since mid-January as COVID-19 cases and COVID-related hospitalizations have subsided.
With the FDA approval in February of our supplemental New Drug Application for our Billerica-based manufacturing facility, we are now producing and distributing DEFINITY manufactured at our on-campus facility in addition to continuing to source from our existing long-term contract manufacturer. The investment in our on-campus facility was strategically driven to ensure supply chain redundancy, as well as to drive margin expansion over time.
I'll speak briefly to AZEDRA before turning over to Paul. During the first quarter, our team worked with nuclear medicine departments at academic centers of excellence in key markets across the US. And we are pleased that two additional centers of excellence have joined the network of centers now offering AZEDRA treatment.
With the COVID-19 pandemic receding and hospital access improving, we are optimistic both physicians and patients will consider treatments with AZEDRA for pheochromocytoma and paraganglioma.
Now, let me turn the call over to Paul for a commercial update on our key products.
Thank you, Mary Anne. And good morning, everyone. During the first quarter, our commercial teams continued to execute on our strategy, namely to establish PYLARIFY as the PSMA PET imaging agent of choice in the US prostate cancer community, maintain market leadership with our Microbubble franchise and deliver on our financial objectives.
Beginning with the PYLARIFY launch, we accelerated our momentum with PYLARIFY sales of $92.8 million compared to $35.4 million in the fourth quarter. We also continued to invest in the brand across supply, contracting, market access and customer adoption.
Our supply and capacity investments included the activation of two additional PET manufacturing facilities, or PMF, during the first quarter, which further expanded our geographic footprint. We have also identified new PMF to supplement our network, expand our footprint and provide redundancy and enhance capacity in existing geographies.
As highlighted last quarter, we continue to expand our capacity at existing PMF sites by investing in additional synthesis boxes. These new boxes allowed us to increase our overall capacity and number of batches produced. We have also been able to improve our batch efficiency and overall batch size, while still selectively flying doses in advance of local PMF activation. Our broad manufacturing network and increased capacity, along with F 18's longer half-life allows us to efficiently and continually meet the needs of our customers.
We believe this ability to meet customer demand, when combined with PYLARIFY being the first and only commercially available PSMA PET imaging agent for almost 10 months, provides us a sustainable first mover advantage.
Within market access, both our passthrough status with the Centers for Medicare and Medicaid Services, or CMS, and our HCPCS code went into effect January 1, 2022. We also continue to make considerable progress with commercial and Medicare Advantage plans, as well as radiology benefit managers, and now believe 90% of covered lives have access to both PYLARIFY indications, well ahead of what is typically seen at this point in a launch. This is an important milestone for PYLARIFY, facilitating its placement in the prostate cancer workflow and ensuring that US prostate cancer patients have access to this game changing product.
In addition, the Society for Nuclear Medicine and Molecular Imaging, or SNMMI, recently updated their appropriate use criteria, noting that the PSMA PET imaging including PYLARIFY can be used for patient selection for PSMA-targeted radioligand therapy. We believe this is an important step to ensure that health care professionals and patients will continue to have access to all approved PSMA PET imaging agents, including PYLARIFY. Our market access team continues to support our customers and payers on relevant coding, coverage and payment-related questions.
During the first quarter, we also continued to execute on customer contracting. And I am pleased to announce we now have contracts in place with 100% of our targeted US academic institutions which treat prostate cancer, as well as many communities hospitals, government facilities and freestanding imaging centers.
These contracts, combined with our demand generating activities, have enabled us to expand the breadth and depth of customer adoption. We have seen significant growth in the hospital outpatient segment following passthrough initiation, with hospitals comprising 70% of year-to-date orders. Independent imaging centers and government facilities comprised 25% and 5% of year-to-date orders respectively. We also remain encouraged by the rate of repeat demand increasing quarter-over-quarter, with over 95% of our customers having ordered multiple doses.
As of the end of the first quarter, almost 700 customers across 45 states and the District of Columbia are actually ordering PYLARIFY on a regular basis. We believe this highlights the impact PYLARIFY is having on patient care and our ability to execute, both in demand generation and supply fulfillment.
We believe PYLARIFY AI will also have a positive impact on patient care and product sales, as it is designed to provide enhanced consistency in quantitative analysis, precise anatomical context and can enable quantitative reporting.
Collectively, these benefits potentially contribute to increased reader efficiency and reproducibility of PSMA PET CT image assessments. We are working with our partner, [indiscernible] and have continued to introduce PYLARIFY AI at key centers across the country.
Finally, I want to provide an update on the total addressable market for PSMA PET imaging agents. The recent FDA approval of Novartis' Pluvicto creates a new addressable market for PSMA PET imaging in patient selection for PYLARIFY targeted therapy. As a result, we updated the US total addressable market or TAM for all PSMA PET imaging to be around 250,000 annual scans, which is an increase of approximately 30,000 scans per year for this MCRPC patient population.
The total market opportunity for PSMA PET imaging is now approximately $1.1 billion. Importantly, this TAM may continue to increase as medical practice evolves and as PSMA therapeutics expand into new indications. We look forward to continuing to be the PSMA PET imaging agent of choice in this large and dynamic market.
As you can see, we continue to execute against our launch priorities and to further establish PYLARIFY as a PSMA PET imaging of choice in the prostate cancer community. And we believe we will hold this position even with the recent availability of competitive agents.
Switching now to DEFINITY. The first quarter saw continued growth in year-over-year sales, even amidst hospital staffing shortages and record COVID-19 levels in January. We saw steady improvement over the course of the quarter in both in-person promotional activity and customer ordering as case counts and hospitalizations decreased. And we believe we have strong momentum coming into the second quarter and remainder of the year.
I will now turn the call over to Bob for a financial update.
Thank you, Paul. And good morning, everyone. I will provide highlights of the first quarter financials focusing on adjusted results unless otherwise noted.
Turning to the quarter. Revenue for the first quarter was $208.9 million, an increase of $116.4 million or 125.8% over the prior-year period.
Earnings per share for the first quarter was $0.97, an increase of $0.92 over the prior-year quarter.
Before providing further details on these results, it is important to note that within these numbers are the impact of the Novartis agreement outlined in our 10-Q filed this morning.
We recorded revenue of $24 million in earnings per share of approximately $0.25 related to this agreement. Therefore, comparable underlying performance to our prior Q1 guidance is revenue of $184.9 million and earnings per share of approximately $0.71.
Turning now to the revenue details and beginning with precision diagnostics. Revenue of $86.2 million were 0.5% higher from the prior-year quarter. Sales of DEFINITY, net of rebates and allowances, were $58.3 million or 0.2% higher as compared to the prior-year quarter and ahead of our previously disclosed expectations.
TechneLite net revenue was $22.6 million, down 0.9% from the prior-year quarter due primarily to the exited contract mid last year with an approximate $2.5 million per quarter impact, offset in part by opportunistic sales in the quarter.
Radiopharmaceutical oncology contributed $94.1 million of sales, up significantly due to the continued rapid ramp in sales of PYLARIFY, as described by Paul. This result also includes a sequentially higher contribution from AZEDRA, up 96.1% over the prior year, which benefited from deferred procedures from Q4 last year, as well as expanded sites of care.
Lastly, strategic partnerships and other revenue was $28.6 million, driven primarily by the Novartis agreement noted earlier, followed by the RELISTOR royalty. The Novartis agreement has been deemed licensing revenue in the quarter for accounting purposes and can be considered a one-time event.
Gross profit margin for the first quarter was 67%, an increase of approximately 1,670 basis points from the first quarter of 2021 on a similar basis. If we exclude the Novartis contribution, gross profit margin would have been 62.7% or better by approximately 1,240 basis points from 50.3% in the prior year. The increase is due mainly to favorable product mix led by PYLARIFY and DEFINITY, offset in part by increased supply chain and logistics costs.
Operating expenses as a percentage of revenue were 1,497 basis points favorable from 40.5% in the prior year to 25.5%, excluding Novartis impact on revenue, driven primarily by operating leverage while investing for sustainable growth in both sales and marketing and R&D. Within G&A, the company has initiated investment in a new ERP platform to drive workflow efficiencies as we grow.
Operating profit for the quarter was $92.7 million or an increase of $83.7 million or 927.3% over the same period prior year.
Total adjustments in the quarter totaled $33.8 million before taxes. Of this amount, $5.6 million and $8.3 million of expense is associated with non-cash stock and incentive plans and acquired intangible amortization respectively. Also in the quarter, we expensed $18.4 million of net contingent liabilities, of which $18.5 million is related to PYLARIFY CVRs, contingent value rights. The remainder is related to acquisition, integration and other non-recurring expenses.
Our effective tax rate was 26% in the quarter. The resulting reported net income for the first quarter was $43 million and $67.8 million on an adjusted basis, an increase of $34 million and $64.5 million respectively.
GAAP fully diluted earnings per share were $0.61 and $0.97 on an adjusted basis, an increase from the prior year of $0.48 and $0.92 respectively.
As noted earlier, excluding the approximate $0.25 impact of these figures due to the Novartis agreement, earnings would have been $0.36 and $0.71 on a GAAP and adjusted basis respectively.
Now turning to cash flow, first quarter operating cash flow totaled $10.3 million as compared to $9.8 million in Q1 2021. Capital expenditures totaled $3.2 million, up slightly from the prior-year quarter.
Free cash flow, which we define as operating cash flow less capital expenditures, was $7.1 million, a decrease of $0.2 million from the prior-year period. As we look forward to the balance of the year, we would expect to begin generating significant free cash flows as month-over-month ramping of PYLARIFY accounts receivables mature into cash receipts.
Cash and cash equivalents, net of restricted cash, now stands at $105.4 million. We continue to have access to our $200 million undrawn bank revolver and are comfortable with our strong liquidity position.
Turning now to our guidance for Q2 and the full year. We forecast revenue to be in the range of $200 million to $215 million for the second quarter of 2022, an increase of approximately 98% and 113% over the second quarter of 2021. We are updating our full-year view to take into consideration actual Q1 performance, as well as quarter-end exit rates for PYLARIFY.
Therefore, we now forecast full-year revenue to be in a range of $800 million to $835 million from the prior range of $685 million to $710 million. This updated range includes not only recognized revenue from Novartis of $24 million recorded in the first quarter, but also the continued adoption of PYLARIFY, which we now model at $385 million to $420 million for the full year. Our increased estimates of PYLARIFY encompasses our expectations of consistent performance amidst competition as well as the continuation of progressive market penetration.
Turning now to earnings. Adjusted EPS should be in a range of $0.67 to $0.73 for the second quarter. We are raising our full-year adjusted EPS to account for a relative Q1 outperformance as well as the incremental contribution from higher PYLARIFY revenue expectations and the adjusted EPS impact of the Novartis agreement of approximately $0.25. We now expect adjusted EPS to be in a range of $2.90 to $3.15 per share versus the prior range of $1.95 to $2.05.
With that, let me turn the call back over to Mary Anne.
Thank you, Bob. In closing, I'd like to leave you with a few key takeaways. First, and notably, I would like to recognize the first quarter of 2022 was a record period for Lantheus for both revenue and earnings. That performance was driven primarily by PYLARIFY, with its strong adoption by the medical community as a true innovation in the management of patients with prostate cancer. We are fully committed in our efforts to further solidify PYLARIFY as the PSMA imaging agent of choice with healthcare providers and the patients they serve.
Second, DEFINITY's steady recovery throughout the quarter and momentum moving forward gives us confidence in the continued growth and contribution of our Microbubble franchise.
Finally, it is strategically important that we continue to advance our portfolio objectives. And this was an active quarter for us with the progress made towards that objective. I look forward to sharing more information with you about these initiatives throughout the year.
Before we open the call to questions, I'd like to take a moment to highlight two recent additions, one to the Lantheus board and one to my leadership team. In March, we were thrilled to welcome mini Minnie Baylor-Henry to the Lantheus Board of Directors. Minnie has a stellar life science resume with regulatory affairs expertise. She's a proven business leader and will be a great add to the current complement of expertise represented by the directors on the Lantheus board.
Earlier this month, I added Dr. Jean-Claude Provost to my leadership team as the interim chief medical officer. With more than 30 years of industry experience, including previous positions at GE Healthcare, Pfizer, Bayer, and Merck-Serono, Jean-Claude will play a critical role in helping execute our strategic vision to find, fight and follow disease to better deliver patient outcomes.
With that, Bob, Paul and I are now ready to take your questions. Operator, please go ahead.
[Operator Instructions]. And our first question coming from the line of Rich Newitter with Truist.
Congrats. Fantastic quarter here. Maybe just to start off on the guidance, which increased significantly, I was hoping, Bob, Mary Anne, can you talk to us a little bit about your approach to how you arrive at that number. Why is roughly $400 million at the midpoint – I suppose, why is that the right number? And specifically, if you could talk to kind of what would get you to the high end of the range? What factors would get you to the low end? Is there any contemplation of the expanded TAM and penetration into the therapeutic use contemplated in this guidance range? And how do we think about kind of the cadence through the year? My estimate gets – it's about $300 million of PYLARIFY revenue that's spread between the remaining quarters? Do we just evenly spread that out? How should we think about that?
I'll start, Rich. And then Bob can get more detailed with numbers. But I think you've touched on some of it. This is a range. We're still in a launch. We're thrilled with what we're seeing. And we're still monitoring and kind of getting our own feedback from market as to how they're adopting to PYLARIFY. All signs are go. And so, we continue to monitor that. And that is what has led us to, as you noted, increase the TAM, along with some of the market events. The approval of Pluvicto was certainly a factor there. But the other factors are the events, the anecdotal events we see in the market around the adoption of PYLARIFY and the intent to use further.
So, I won't dive into the financial pool and tell you what to do with your model. But I'm not sure I would evenly spread that $300 million over the next three quarters, but I'll let other Bob jump in there.
I guess my scripted remarks were somewhat purposeful in how I laid out the comments. One, we continue to look at exit rates in terms of where we were month by month. This is a month-by-month ramp. Every month seems to be just that much better than the last. But we are sitting here at the end of April, there's still many more months to go. So, as we thought about going forward, I use the words that we encompassed expectations for consistent performance. So, in other words, if we were to continue to – because of competition, that we're able to sort of continue to deliver what we've already managed to do, knowing that we will continue to add PMF throughout the balance of the year, that would get you towards the low end of the range. If we see continued market penetration, so i.e. as we think through Qs 2, 3 and 4, yes, the implications are that Q2 is higher than what was in Q1 just by the math. And then I would expect the second half to, as we said, either be consistent with the first half or can continue to grow in the same fashion that we've seen thus far.
The other thing from a full year perspective, which is not a PYLARIFY thing, just keep in mind that the full-year number now takes into consideration that $24 million from the Novartis agreement. So, as you think through your model, that's a one-time number, but that's embedded in that $800 million to $835 million number as well.
But importantly, not embedded in the PYLARIFY number?
No.
And I think, Mary Anne, you suggested that there was some incremental contribution post the Pluvicto approval contemplated in that guide, you're assuming that you will have access to that market. Congratulations on the SNMMI update there. But are you assuming some contribution and use in that part of the market?
What I'm really comfortable saying, Richard, we're very comfortable that PYLARIFY and the other PSMA agents will holistically be included in consideration for PSMA targeted therapeutics. As you note and as we noted in our remarks, the SNMMI guidelines have already come out with that. And we expect NCCN to also update their guidelines briefly within a short period. We believe that both those sets of guidelines, as well as practice, will consider the PSMA imaging agents holistically when considering patient selection for PSMA targeted therapeutics. But I did not meant to infer that our guide or our numbers specifically include contribution from that. We increased the TAM, the total addressable market for consideration, but I wasn't trying to infer that we specifically include the contribution from that in our updated numbers.
And if I could just squeeze one more, any timing or updates on some of these clinical collaboration efforts with Novartis that you highlighted upfront? Anything that we can expect in 2022 or updates, that would be helpful.
All of those will fall under – normally, when we refer to PYLARIFY that we refer to PyL because we've tried to differentiate critical use versus commercial use. And as we mentioned, I'm not sure if it's the scripted remarks here, but we certainly have been transparent about that. At this point, PYLARIFY is well established for use in all late stage clinical PSMA targeted therapeutic trials that are being conducted in the market, and so that will be a source of volume. But, again, that is not really what's driving our revenue guides. Our revenue guides are being are being driven by the commercial uptake for medical use.
And our next question coming from the line of Danielle Antalffy with SVB Leerink.
And I will echo Richard's sentiments. Congrats on another amazing quarter. I guess one question I have is, as we look ahead to the May 17 Analyst Day, not asking you to really front run, but, Mary Anne, if there's any way you could preview what we should expect to be hearing. Is it really about what we know within the existing product portfolio or are we going to talk about sort of what's next beyond the current PYLARIFY indication? Any color on what we might hear on May 17? And then I have one follow-up.
May 17 is going to be a very exciting day and it's our intent to really take the audience through our rationale for isotopes, or as we call them now, radioligand therapies and really kind of help everyone understand how these products, whether it's diagnostically or therapeutically, are truly being embraced now in life sciences and how as a company Lantheus' strategy is to be forefront in that. It's a really exciting time for healthcare. We've seen that now with – we have our first approval with Novartis' approval of Pluvicto. That is the first of what will be the knock on therapeutic side. We have the approval of PYLARIFY from last year, which I think really speaks to, we believe, the – the uptake of PYLARIFY speaks to how welcomed this innovation is in prostate cancer, and there's more to come. And so, that's what we're hoping – among other topics, that's what we're hoping the Investor Day will really help shed some light on for our analysts and for the investors who will share the day with us.
I guess my follow-up was going to be on the TAM. Based on your guidance, you're going to be somewhere around 35%, 40% penetrated. 40% of the $900 million, but, obviously, less of the $1.1 billion. So, what's next for PYLARIFY? I guess stay tuned for May 17?
I would stay tuned and keep you really eager to come.
I just have one DEFINITY question. I'm not sure if you guys have given this color in the past. But any way you can – I know this is a tough – any way you could quantify as best you can sort of what you do [Technical Difficulty] COVID impact is and has been on that product and what we should be thinking for steady state growth once we're sort of – once COVID is more in the rearview mirror here?
I'll start and then I'll kick it over to Paul. So, just from a from a numbers perspective, the growth rate of 4.2% encompasses that early impact in the quarter. And in fact, it was maybe even slightly less, like I said, than we expected. My prior guidance was that it would be flat based on what we were seeing. But we saw some robust rebounding in volumes as we went through. And so, of note, even though I didn't state it specifically, our view of DEFINITY for the full year remains intact, in the sense that we would still be expecting what I think I had previously noted as high-single digit, low-double digit growth. And so, what that then means is that, as we go through Qs 2, 3 and 4 that we're going to be at robust rates to lift up from where we are here in Q1. So, we remain very confident about its current trajectory. Paul?
As Bob mentioned, we did see steady improvement over the course of the quarter. If we look at COVID case counts and hospitalizations, we were at all-time highs in Januarys, which impacted our ability to be in hospitals and physicians' offices, promoting and detailing the product. As we saw cases and hospitalizations reduce over the course of the quarter, we in turn saw increased promotional activity, meaning in-person activity, and we saw greater utilization in our customer base. And we would expect that to continue as counts remain low and hospitalizations remain low. Naturally, we continue to monitoring the overall staffing situation, but we believe we have significant momentum coming into the second quarter.
And our next question coming from the line of Zach Wiener from Jefferies.
Congrats on another great quarter. Just on the competitive landscape for PYLARIFY, there's two other products coming to market in the second half. Can you just speak to how we should think about the second half of the year with these products coming to the market?
Zack, this is Mary Anne. I'll start and then we can turn over to Bob or Paul where we think the question goes best. We welcome competition into the market. As we've seen with the TAM, this is a large market. It's a growing market. There's still awareness to be built out there around the availability of PSMA PET imaging patients. So, for us, it's almost, in that sense, good news to have others out there, helping us with creating that awareness. Having said that, we are absolutely confident that we will remain the leading PSMA PET imaging agent of choice and it's our intent to have that be clear, not only to the market, but in the results that we've continued to post with that.
I'll turn it over to Paul for additional comments there.
I think I would echo what Mary Anne said, right? We've been thrilled to be the first commercially available PSMA imaging agent for almost 10 months. We remain focused on execution of PYLARIFY and we've always contemplated that we would have competition. We do think that, given that PSMA PET imaging is a relatively new modality for US prostate cancer patients, having additional voice out in the marketplace to raise awareness is a good thing to enhance the market and to raise awareness.
The recent two competitive approvals represent the third and the fourth gallium-based PSMA PET imaging agent and we remain confident that as the only F 18 approved isotope for PSMA PET imaging with a significant distribution and scale advantage that better match marketplace dynamics that we're going to be able to continue to lead going forward.
So, we welcome the continued interest. We're also incredibly excited about expanding therapeutic options and, in turn, diagnostic opportunities and continue to remain confident that we can remain the PSMA PET imaging of choice in the community.
One more just on the PMF side. I know you ended last year with 80% of the country covered, and I think you're moving away from talking about that number, but is the comment now that the percentage of the country that is covered, that growth will slow, but the more high density population areas, you will continue to add additional cyclotrons to drive increased [indiscernible] usage. Is that the thought?
So, I can take that. So, we will continue to add PMF coverage to expand our geographic coverage. That said, right, we already have the vast majority of the US covered as I think I highlighted. PYLARIFY patients have and continue to be treated in 45 patients in addition to the District of Columbia. And so, we have a significant distribution network that already covers there. I think when combined with our market access progress, where 90% of covered lives have access to PYLARIFY, we remain focused on continuing to add new customers and we do that on a regular basis, but ensuring that we also increase the breadth and depth of the penetration going forward. So, I think it's right to say that we will add capacity, we will add redundancy, and we will continue to focus on adding and supporting new customers and using PYLARIFY.
And if I could sneak one more in just on – can you give some comments on PYLARIFY in the O-US landscape and what that timeline potentially looks like? I know it's through a partnership.
Zach, it is through a partnership. Curium is our partner in the EU, which is the other major medical market here for PSMA imaging agents. I can't offer a specific timeline because I can't speak for the company. I can say they are phase three with the product and I can say confidently that their intent is to bring it to market in the EU. There is appreciation in the EU for PSMA-based PET imaging agents. And in fact, as folks may remember from our comments before launch, the guidelines in Europe actually reflected – before the guidelines in the US, the guidelines in Europe reflected the preference for PSMA-based PET imaging agents over other modalities as the preferred modality to use in the diagnosis and management of prostate cancer patients. So, look, we support our partners, we look forward to that, but I can't offer a specific timeline for them.
Congrats on the quarter.
And our next question coming from the line of Larry Solow with CJS Securities.
I want to echo my congratulations. I guess the first question I have is just a little quick follow up on PyL competitive landscape. And I don't know how well you can answer this question. But it feels like you're taking most of your – get your market share gains today from Axumin, the other PET imaging agent. Or are you also perhaps taking some share from more traditional CAT scans, ultrasounds. It doesn't seem like the gallium-based are having much – I don't know if they've really been on the market, even though a couple have been approved. But I guess my second part of that question is, as we look out competition maybe will have to come from the F 18 side. What is the sort of the nearest competition on fluorine 18 based agents?
Just so it's clear for everyone, when we talk about the TAM and when we talk about – whether we're talking about scans or patients, that is across all modalities, so that is inclusive of historically what modalities have been used to image prostate cancer patients. When we look at the success that we've had with PYLARIFY, I think it's fair to say that PYLARIFY has been used instead of all of those modalities. Now, to what specific extent for each of them, I can't quantify. But if you look at just the uptake and the intent of physicians, I think it's fair to say that if you compare to the other modalities that had been previously used to image prostate cancer, PYLARIFY has taken share every one – kind of derive it from all of them.
I think if I were to expand on…
Paul wants to add a comment there.
I think we think of this as taking share from previous non-PSMA modalities, specifically in the recurrent population. Right? And so, I think we're taking share from all of those modalities, as well as non-PSMA PET imaging that you referenced. But I think, importantly, the metastatic indication is a new indication for the marketplace within PET imaging that we received last May. And so, this has been about taking share, but it's most importantly about expanding the marketplace. And as you can see, the total addressable market continues to increase as the PSMA agent of choice. We continue to take share as well as to build the marketplace to stress the advantages of this important modality and PYLARIFY specifically.
My second part of that sort of long winded question was, it does seem like F 18 is superior? So, perhaps gallium-based with their supply issues, the sort of – at least in the near term seem to be on the backburner there. But perhaps another F 18 [Technical Difficulty] compete better with you guys. Do you have just a brief sort of outlook on when some of those – when that competition could potentially enter the market.
And your comments are well noted there, Larry. There is another that we're aware of another F 18 based product under development. To our knowledge, it's still in its phase 3 program, after which it completes, it will require submission to the FDA. We would not anticipate it would be offered priority review since that was before the novel entrance into a category, which is what we were offered. So, from a timeline perspective, I don't think we anticipate at all that we would see that agent anytime in 2022, at least.
I've got a question for Bob. Just on the guidance, and not to split hairs, because, obviously, great outlook and all, but just on the Q2 guidance, specifically, if we just compare sequentially, if you sort of strip out the strategic $24 million that you mentioned from Novartis, you kind of did like $180 million – I think $184 million you said. So, $185 million and $0.70, just to use round numbers. And your guidance next quarter is like, midpoint is, what, $207 million and $0.70. So, is there any reason – looks like margin going down a little bit, is there higher cost or anything? Or how should I kind of decipher that?
It's actually slightly higher costs in the OpEx aspect of things. So, one, we're letting Paul have funds to – we mentioned the collaboration that we have. Those expenses start to really kind of be in Q2. Our ERP investments, that is more ramping here in Q2 as well. So, I think the gross margin number that we provided is sustainable. And so, as you go forward from modeling, then you should see that drop through continuing, particularly as we see DEFINITY and PYLARIFY both continuing to grow according to our expectations. But we'll have slightly higher levels of investment. And that was purposeful and we thought that was important to help to continue to drive the growth during the year, but also to set ourselves up for technology advancements that we think can drive more workflow efficiencies for the company longer term.
Sounds like discretionary investments to drive future growth. It makes 100% sense. Just last question, any update on DEFINITY in terms of the room temperature or the in-house manufacturing? I know you've, I think, sold a little bit of both. And I don't expect you to give quarterly updates every quarter, but anything you can mention on those two?
As I offered in my remarks, Larry, we now are shipping from our on-campus facility. So our supply chain for DEFINITY of, say, original formulation is now sourced both from our Billerica facility as well as from our longstanding contract manufacturer. From a RT perspective, as I've noted somewhat continuously, it's not our intent to break out the two formulations and offer information on specifics to the two. Our offering is out to our customers for choice of formulation. We are continuing to execute that with our customers. And as I said, we'll leave it to their choice. I don't anticipate at any point in the future we will be offering detailed information on the split of use of those products in the marketplace.
[Operator Instructions]. And we have a follow-up question from Rich Newitter with Truist.
I just wanted to ask on pricing for PYLARIFY. Is that all coming in as expected? Or can you comment there at all? And then also, just on legislation that I believe is sitting in Congress right now, The FIND Act, for potentially amending or modifying transitional passthrough for radiopharmaceuticals, any updates or views on prospects for that kind of moving through and when?
I will say pricing is where we expect it to be. As you know, we don't speak to pricing specifically, but I am okay with sharing that. It is where we expect it to be.
On The FIND Act, I like The KIND Act, which it certainly would be. But the actual name is The FIND Act. It continues to move forward. We continue to add support. We work with our advocacy to add support and we continue to see progress there. I don't know, Paul, if you want to add any additional comments on specifics with that.
This is an active source of involvement for our government affairs organization, as you may be aware, The FIND Act has now been introduced on the floor of both the House and the Senate with significant bipartisan support and sponsorship. And so, we are hopeful that this will become law in the coming months or year. And then that would have a notable impact on the passthrough dynamics to ensure that CMS continues to reimburse for innovative radiopharmaceuticals going forward.
If I could just follow-up on that, Paul. So, let's just say it goes through and traditional passthrough is done away with, what are the mechanics of what that does and how that impacts price and what it does for you and the market?
We are going to be talking more about this on Investor Day. But let me provide some more information here. First and foremost, I think it's important to understand that passthrough as a payment dynamic only applies to traditional Medicare payment in the hospital outpatient segment. And so, that really is a minority of the patient population that is being treated for prostate cancer. When you think about the number of commercial payers, when you think about alternative sites of care, whether they're government facilities or whether they are freestanding imaging centers and when you also note the increasing share that Medicare Advantage is having and we've seen that rise and expect in the coming years to be almost 50%. So the patient population that actually in their site of care and through their insurers is a minority. It's around a quarter of the population. And so, I don't want to overstate the importance.
But what I do think is important is if The FIND Act is passed, then at the end of the 36 month or three year, if you will, clock, then there is not a payment adjusted. This does not impact coverage in any way. This is strictly a Medicare hospital outpatient payment from CMS for traditional Medicare that would impact payments to hospitals. And so, I'm not going to speak about the specific financials of a hospital system. But the passage of The FIND Act could positively influenced their desire to continue to use novel radiopharmaceuticals even after passthrough ends in the current construct.
[Operator Instructions]. I'll turn the call back to Mary Anne for any closing remarks.
Yes, thank you, everyone, for joining us on today's call. I would like to remind you that we will be webcasting our inaugural Investor Day on May 17 where members of the Lantheus management team including myself as well as key opinion leaders will provide what we'll see is an in-depth review of our prostate cancer and Microbubble franchises as well as our overall business and financial strategy.
And I think that concludes my remarks for today.
Thank you, ladies and gentlemen. That does conclude our conference for today. Thank you for your participation. You may now disconnect.